Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telbivudine vs Telbivudine + Valtorcitabine in Chronic Hepatitis B
NCT00128544Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2005
- Primary completion
- May 2007
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of Valtorcitabine in Chronic Hepatitis B (CHB) (2 arms), sponsored by Novartis. Primary endpoint: Reduction in Serum HBV DNA at 52 weeks. Started May 2005; status: completed.
02
Drugs
Valtorcitabine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT00128544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00128544.